Articles: covid-19.
-
To date, there has been little agreement on what drug is the "best" drug for treating severe COVID-19 patients. This study aimed to assess the efficacy and safety of different medications available at present for severe COVID-19. ⋯ This study suggested that ivermectin/doxycycline, C-IVIG, methylprednisolone, interferon-beta/SOC, interferon-beta-1b, convalescent plasma (CP), remdesivir, lopinavir/ritonavir, immunoglobulin gamma, HS, auxora, and imatinib were efficacious for treating severe COVID-19 patients. We found that most medications were safe in treating severe COVID-19. More large-scale RCTs are still needed to confirm the results of this study.
-
Chinese medical journal · Oct 2022
Meta AnalysisAssociation between influenza vaccination and SARS-CoV-2 infection and its outcomes: systematic review and meta-analysis.
World Health Organization recommends that influenza vaccines should benefit as much of the population as possible, especially where resources are limited. Corona virus disease 2019 (COVID-19) has become one of the greatest threats to health systems worldwide. The present study aimed to extend the evidence of the association between influenza vaccination and COVID-19 to promote the former. ⋯ PROSPERO, CRD42022333747.
-
Eur. J. Clin. Invest. · Oct 2022
Review Meta AnalysisRisk of reinfection and disease after SARS-CoV-2 primary infection: meta-analysis.
A precise estimate of the frequency and severity of SARS-CoV-2 reinfections would be critical to optimize restriction and vaccination policies for the hundreds of millions previously infected subjects. We performed a meta-analysis to evaluate the risk of reinfection and COVID-19 following primary infection. ⋯ A strong natural immunity follows the primary infection and may last for more than one year, suggesting that the risk and health care needs of recovered subjects might be limited. Although the reinfection rates considerably increased during the Omicron wave, the risk of a secondary severe or lethal disease remained very low. The risk-benefit profile of multiple vaccine doses for this subset of population needs to be carefully evaluated.
-
Journal of critical care · Oct 2022
Meta AnalysisAssociation between timing of intubation and clinical outcomes of critically ill patients: A meta-analysis.
Optimal timing of intubation is controversial. We attempted to investigate the association between timing of intubation and clinical outcomes of critically ill patients. ⋯ Avoiding late intubation may be associated with lower mortality in critically ill patients without COVID-19.
-
Meta Analysis
Comparison of chest CT features between progressive and nonprogressive patients with COVID-19 pneumonia: A meta-analysis.
The aim of this study was to compare the radiographic features of patients with progressive and nonprogressive coronavirus disease 2019 (COVID-19) pneumonia. ⋯ Nodules, crazy-paving pattern, and/or new lesions in bilateral, upper and middle lobe of right lung, and lower lobe of left lung may indicate disease deterioration. Clinicians should formulate or modify treatment strategies in time according to these specific conditions.